metastatic hormone-sensitive prostate cancer
New Approval for Darolutamide
The FDA approved an additional indication of darolutamide (Nubeqa, Bayer) in combination with docetaxel for the ...
AUGUST 18, 2022
Darolutamide Triplet Therapy Improves Survival In mHSPC
Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and ...
APRIL 12, 2022
Load more